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Abstract
Background: Lipid-lowering medication remains underused, even in high-risk populations. The
objective of this study was to determine factors underlying general practitioners' decisions not to
prescribe such drugs to patients with type 2 diabetes.
Methods: A qualitative study with semi-structured interviews using real cases was conducted to
explore reasons for not prescribing lipid-lowering medication after a guideline was distributed that
recommended the use of statins in most patients with type 2 diabetes. Seven interviews were
conducted with general practitioners (GPs) in The Netherlands, and analysed using an analytic
inductive approach.
Results: Reasons for not-prescribing could be divided into patient and physician-attributed factors.
According to the GPs, some patients do not follow-up on agreed medication and others object to
taking lipid-lowering medication, partly for legitimate reasons such as expected or perceived side
effects. Furthermore, the GPs themselves perceived reservations for prescribing lipid-lowering
medication in patients with short life expectancy, expected compliance problems or near goal lipid
levels. GPs sometimes postponed the start of treatment because of other priorities. Finally,
barriers were seen in the GPs' practice organisation, and at the primary-secondary care interface.
Conclusion: Some of the barriers mentioned by GPs seem to be valid reasons, showing that
guideline non-adherence can be quite rational. On the other hand, treatment quality could improve
by addressing issues, such as lack of knowledge or motivation of both the patient and the GP. More
structured management in general practice may also lead to better treatment.
Background
Statins can lower cardiovascular events in patients with
diabetes mellitus by around 25%.[1] Treatment guide-
lines for general practitioners in The Netherlands have rec-
ommended prescribing lipid-lowering drugs to almost all
patients with type 2 diabetes mellitus. Despite these rec-
ommendations, the number of patients being treated has
remained rather low. Studies in Dutch general practice
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showed that many diabetes patients were not receiving
statin treatment.[2,3] Low percentages of prescribing are
also seen in other countries.[4,5]
Not prescribing medication as recommended by guide-
lines is sometimes considered suboptimal care but it may
be deliberate and justified. Several models have been sug-
gested to explain why physicians do not act according to
recommendations. There is the framework as proposed by
Cabana et al that recognizes internal barriers, such as lack
of knowledge or motivation of the physician, and external
barriers, including patient, guideline, and organisational
factors.[6] On the other hand, there is the concept of 'clin-
ical inertia' which has been delineated as a problem of the
health care professional and the health care system.[7] For
quality improvement, it is important to differentiate
between clinical inertia and appropriate care.[8] There
may be good reasons for not prescribing a lipid-lowering
drug in specific cases, such as patient-specific conditions
that would preclude the use of such drugs. In addition, it
may be the patient who refuses to take treatment, thereby
preventing the physician from prescribing the recom-
mended treatment.
Several studies have investigated barriers to prescribing
lipid-lowering drugs. [9-11] In general, GPs mentioned
concerns about cost, workload, patient compliance and
medicalisation as barriers.[9] In patients with ischaemic
heart disease, organisational barriers were considered to
be important, but also errors and omissions by GPs and
patient reluctance or concerns were seen as important bar-
riers.[10,11] It is not known whether the same reasons
apply for not prescribing lipid-lowering medication in
patients with diabetes.
The purpose of this study was to explore reasons why gen-
eral practitioners (GPs) do not follow guideline recom-
mendations regarding lipid-lowering treatment in
patients with type 2 diabetes mellitus. We used in-depth
interviews related to real cases to study the whole spec-
trum of physician, patient and practice-related barriers as
perceived by the GPs.[6,12] Specifically, we tried to gain
further insight into the factors that may or may not repre-
sent appropriate care, since only the latter should be
addressed to improve the quality of care.[8]
Methods
Design
We conducted a qualitative study using semi-structured
interviews to explore the reasons of general practitioners
(GPs) for not prescribing lipid-lowering medication to
specific patients with type 2 diabetes mellitus. The
research project was checked by the METc office of the
University Medical Center Groningen (UMCG) who
declared that the study fulfills all requirements for patient
anonymity, and was in agreement with regulations for
publication of patient data. According to the Dutch Code
of Conduct for Biomedical Sciences, all patients with type
2 diabetes mellitus of the participating GPs have been
informed that information from their medical records was
going to be used for research purposes, and they were
given the opportunity to opt out. Less than 0.5% of all
patients have been excluded for this reason.
Participants and setting
Evidence-based treatment guidelines are disseminated
among all GPs in the Netherlands. The study was con-
ducted in a region in the north of the Netherlands, where
a guideline was distributed in October 2004 that recom-
mended the use of statins in patients with type 2 diabetes.
Between October and December 2005, interviews were
held with GPs who had indicated that they were familiar
with these guideline recommendations. GPs were selected
according to a method of purposeful sampling to include
variation concerning practice (single-handed or group
practice), practice location (city or rural area), and diabe-
tes management (with or without a nurse practitioner).
Interviews were conducted until data saturation was
reached and no new themes emerged.
Data collection
Interviews were held in the GP practice by EAB and
recorded on CD-rom. All interviews were transcribed ver-
batim by the interviewer. Before the interview, a coded list
of all patients with type 2 diabetes was extracted from the
electronic medical records and screened for patients not
being prescribed lipid-lowering medication. These coded
cases were discussed in the interview, during which the GP
was able to access the medical record to identify the coded
patient. Starting with an open question, the GPs were
asked to elaborate why that particular patient did not use
lipid-lowering medication. Possible topics raised
included patient-related factors, such as risk factor levels,
comorbidity, medication issues, personal circumstances,
and GP-related factors, such as beliefs and attitudes
towards (preventive) medication, and perceived organisa-
tional barriers. The duration of the interviews was approx-
imately one hour. Sometimes not all patients from the list
were discussed because of lack of time. At the end of the
interview, the GPs were asked if they had any other argu-
ments or reasons for not following the guideline recom-
mendation on lipid-lowering treatment.
Analysis
The interviews were analysed by EAB and TV using content
analysis. Both researchers independently examined the
first transcripts before coming together to discuss, modify
and agree on a coding frame. After three interviews, a cod-
ing frame was developed that distinguished between
themes related to the patient as the person deciding not to
use medication (patient-attributed factors) and themes
that were related to the physician as the one who prima-BMC Family Practice 2009, 10:24 http://www.biomedcentral.com/1471-2296/10/24
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rily determined this decision (physician-attributed fac-
tors). Within these groups, themes were clustered around
different general intentions regarding the use of lipid-low-
ering drugs. These differentiations were considered rele-
vant for identifying targets and factors that can be
addressed in order to improve the quality of care. PD crit-
ically examined the framework to improve its clarity and
consistency. Transcripts were reread and coded by EAB
and TV after the final coding frame was established. Newly
collected data were compared with previously collected
data and coding. To ensure consistent coding, the two
reviewers came together to discuss their final coding. PD
reviewed subsets of data to check for accurate coding.
Kwalitan version 5.0 was used to support the qualitative
analysis.
Results
In total, three GPs refused to participate for reasons of
time constraints. Interviews were conducted with 7 GPs,
with no new themes emerging in the last interviews. Of
the interviewed GPs, 2 worked in single-handed practices,
4 in a city, and 5 had a nurse practitioner. Three of the GPs
were female, and their age ranged from 31 to 55 years.
For each GP, between 10 and 27 patients with type 2 dia-
betes could be identified that were not being prescribed
any lipid-lowering medication, constituting 13–39% of
the total number of DM patients in these practices. In
total, 16 themes emerged that were grouped in patient
and physician-attributed factors. Each GP mentioned
between 7 and 10 different themes.
Within the group of patient-attributed factors, five themes
were grouped in two categories as presented in Figure 1.
Most GPs mentioned that although patients initially may
agree on taking the medication they do not always act
accordingly. This was referred to by some GPs as inten-
tional non-compliance, but also lack of sufficient knowl-
edge or understanding was mentioned as an underlying
reason for the patient-attributed discontinuation of med-
ication:
"Oh, I probably said that it [the cholesterol] was alright and
then she thought is was alright to stop, something like that,
that's possible? That happens: they think everything is in order
again." [GP6]
Furthermore, most GPs experienced patients who were
not willing to start with this medication at all, because of
expected or perceived side effects, preference for alterna-
tive medicine or unclear reasons.
"Despite his very serious diabetes, mister Y refused any medica-
tion for years. It took me a lot of effort to get him an appoint-
ment with our nurse practitioner. He prefers to use earthnuts
from Surinam rather than medication." [GP3]
In addition to these patient-attributed factors, there were
many concerns and issues raised by the GPs themselves
for not being able or wanting to prescribe lipid-lowering
medication. Eleven themes grouped in three categories
emerged from the analyses (Figure 1). All GPs saw prob-
lems of structural or organisational origin which limited
the implementation of the guideline recommendation in
daily practice. In such cases, the GP was not opposed to
prescribing lipid-lowering treatment but had not yet done
so for various reasons. These included insufficient knowl-
edge of the guideline recommendation, lack of perceived
responsibility, and lack of structured management to ini-
tiate timely changes in treatment:
"Yes, mister Z, he just uses eh...yes right, he uses a diet only and
he is doing very well. The question is eh, I wouldn't know,
should we give people with diabetes, who are doing well on a
diet, should they take Zocor [simvastatin]?" [GP2, insufficient
knowledge]
"but that patient is monitored by the internist, and I do not reg-
ularly check those patients regarding their lipid-lowering medi-
cation, because I feel that if they are monitored by the specialist,
he has to take care of that." [GP6, lack of perceived responsi-
bility]
"Yes, he was also going to the internist for this. And he has just
not started [a statin] then. Also not later. Now he is with our
diabetes nurse, and she is using a protocol, so I think he will get
one soon." [GP1, lack of structured management]
"Well, if I look at this, I realize I must watch this closer.
Because there are a number of people who actually should take
a statin" [GP7, lack of structured management].
Furthermore, all GPs questioned the value of lipid-lower-
ing medication in some patients, either because of indi-
vidual drawbacks or because of general concerns
regarding the benefit/risk ratio of this medication in
patients with a short life expectancy:
"Considering her prognosis, suffering from breast cancer as well
as Alzheimer, this has not even been taken into consideration."
[GP4, individual drawbacks]
"Well, people who, eh, have a very short life expectancy, I will
not start to bother." [GP5, general reservation relating to short
life expectancy]
"So that she might live a month or two longer, at 95? Because
that's what we are talking about. Prolonging life, well I think
that is nonsense." [GP3, general reservation regarding benefits
in the very old]
"So old, and by that I mean at least over 90, but maybe also
over 80, ramshackle, and morbid and for that reason have aBMC Family Practice 2009, 10:24 http://www.biomedcentral.com/1471-2296/10/24
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lower quality of life. Some of these people find it is highly desir-
able that it ends in a while. That life stops. It is okay. They have
lived their life...." [GP2, general reservation related to quality
of life]
A more explicit disagreement with the guideline recom-
mendations was also expressed by some GPs, for instance
in relation to patients with near goal lipid levels:
"Well, his cholesterol was quite low, it was 4,5...mwah.. then I
think, he doesn't really need it, and this is probably not in line
with the guideline or standard practice". [GP6]
Furthermore, there were fears of non-compliance men-
tioned in combination with reserved attitude towards
lipid-lowering medication:
"There is a fair chance that she cannot keep track of all her
medication and she will make mistakes. I think this doesn't
weigh up to the relatively small advantage of a lipid-lowering
drug." [GP4]
Fear of side effects or of treatment non-compliance were
also mentioned as reasons not to start lipid-lowering
medication at that moment:
Patient and physician-attributed factors for not initiating or continuing lipid-lowering therapy Figure 1
Patient and physician-attributed factors for not initiating or continuing lipid-lowering therapy.
Patient-attributed 
Factors 
Treatment non-compliance / 
discontinuation 
Patient agreed in taking but does 
not act on it because 
Not enough knowledge 
Expected or perceived side effects  
Preference of alternative medicine 
Patient does not want to start 
because 
Rejection for unclear reason 
Physician-attributed 
Factors 
Not enough knowledge of the guideline
Not his/her primary responsibility 
Not enough structured management 
GP is inclined to follow the 
guideline but does not because 
No clear reason 
A contra-indication 
Not contributing to quality of life /  
short life expectancy 
Disagreement with the guideline 
recommendation 
GP does not want to prescribe 
this medication because 
Fear of treatment non-compliance 
Fear of side effects 
Fear of treatment non-compliance 
GP does not want to prescribe 
yet because 
Priority other current diseases BMC Family Practice 2009, 10:24 http://www.biomedcentral.com/1471-2296/10/24
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"...you should not give all at once. Take a new diabetes patient:
if you were to follow the guidelines, he would leave your front
door with 4 different pills. Patients won't buy that, I think. You
have to let them get used to it, little by little. But this gentle-
man's compliance is very bad, so you have to handle this care-
fully..." [GP6]
Finally, priorities regarding other current diseases were
mentioned by most GPs for not yet wanting to start with
lipid-lowering medication:
"Well, it was more a matter of life and death than eh.. worrying
about that kind of stuff.." [GP5]
Discussion
Although the Dutch treatment guidelines recommend pre-
scribing lipid-lowering medication to almost all patients
with type 2 diabetes mellitus, around one third of the
patients of GPs in our study were not using such medication.
This shows that there is a substantial group of high-risk
patients that may benefit from lipid-lowering medication
but are not receiving such treatment. The reasons for not pre-
scribing lipid-lowering medication to diabetes patients as
perceived by GPs could be divided into patient and physi-
cian-attributed factors. According to the GPs, some patients
just do no follow-up on agreed medication and others object
to taking medication in general, partly for legitimate reasons.
In addition, the GPs also perceived intrinsic reservations for
prescribing lipid-lowering medication in some of their
patients, some of which can be seen as appropriate care, and
others that are a target for quality improvement. Often, GPs
were not opposed to prescribing lipid-lowering treatment
but had not yet done so for various reasons.
According to the GPs, some patients influenced their pre-
scribing in a direct way, by not wanting to start or continue
using lipid-lowering medication. Patients' reluctance to take
medication has been identified before as a barrier for ade-
quate treatment,[10,13] and may be difficult to change. On
the other hand, patients' discontinuation of treatment due to
lack of knowledge forms an obvious target for improvement.
In some cases, patients may have sound reasons for not
wanting treatment, such as previously experienced side
effects. They may also reject lipid-lowering treatment in gen-
eral. It has been shown that even well-informed, highly edu-
cated patients with diabetes may decide not to take
statins.[14] From a shared-decision making point of view,
GPs do have to accept such refusals as a legitimate reason for
not prescribing. Costs can also preclude patients from taking
medication. However, at the time of our study, patients in
The Netherlands did not have to pay for this type of chronic
medication.
Patient factors also affect prescribing in more indirect
ways. GPs expressed a reluctance to start (additional)
treatment in patients because of fears of non-compliance.
Such concerns have been mentioned before,[9] but it has
also been shown that GPs sometimes make inaccurate
assumptions and guesses about patients' beliefs and pref-
erences.[13,15] GPs therefore need to check such assump-
tions with the patient. In some cases, it might indeed be
wise not to start too many drugs at once. There can be
other priorities in general practice that warrant more
immediate attention. Competing demands have been
shown to interfere with diabetes care, and general practice
has been described as a balancing act that requires priori-
tization and goal setting by both patient and physician
during each encounter.[16] Therefore, postponing the
start of lipid-lowering treatment can sometimes be seen as
a good decision. From our study results, we can not con-
clude whether the delay was always reasonable or accept-
able. Moreover, little is know about the increased
cardiovascular risk created by delay of preventive treat-
ment.
Some patient-related factors form valid reasons for not
prescribing a specific drug. As was seen in other popula-
tions, medication factors including contra-indications,
side-effects and interactions may prevent a physician from
prescribing.[8,10] In general, such medication related fac-
tors do not preclude GPs from taking appropriate action
but in some cases no alternative medication may be avail-
able.
Patients' age is a recurrent issue related to undertreatment
for cardiovascular diseases.[17] Despite the fact that more
evidence is emerging that elderly patients may benefit
from statin treatment, many physicians express reserva-
tions to prescribing these drugs to patients over 80 years
of age. Besides questioning the benefits of lipid-lowering
medication in this age group, quality of life and life
expectancy clearly play a role in the decision to prescribe
preventive treatment.[10] Benefits from treatment are not
to be expected in the short term. Patients with a short life
expectancy are legitimately not prescribed lipid-lowering
medication. All guidelines do recognize this reason for
deviating from the recommendations. Prolongation of life
is not necessarily wanted, but from our study it is not clear
to what extent the patients were actually involved in this
decision. Older age in itself should not exclude patients
from receiving therapy, but in the frail elderly the risks
may outweigh the benefits of starting preventive treat-
ment.[18]
GPs who do not start lipid-lowering treatment in patients
with near goal lipid levels, could be viewed as disputing
the considerations made in the guidelines. This type of
disagreement has been observed before regarding the start
or intensification of antihypertensive and glucose-lower-
ing medication in patients with diabetes.[19,20] ReportedBMC Family Practice 2009, 10:24 http://www.biomedcentral.com/1471-2296/10/24
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reasons for inaction in these studies included "patient
improving or near goal" and "patient doing well or only
borderline hypertension". Also regarding lipid-lowering
treatment in patients with diabetes, some GPs expressed
that they might postpone prescribing because of margin-
ally elevated risk factor levels.[21] This 'near goal is good
enough' attitude was also found to be associated with the
decision not to intensify lipid therapy.[22] Although one
could defend this attitude, some physicians appear to
accept quite high risk factor levels.[19,20] More impor-
tantly, for lipid-lowering medication, the cholesterol level
should not be the main factor influencing the decision.
Statins have shown to reduce cardiovascular risk in diabe-
tes patients regardless of their lipid levels.[1] Our study
shows that the doubts that GPs have expressed regarding
the value of statin treatment in general,[9] are also present
regarding the high risk group of patients with diabetes.
Our study also showed that some GPs are uncertain about
the exact recommendations in the guidelines. Although this
so-called lack of knowledge could be interpreted as lack of
information, it is more likely to be a problem of information
overload. Confusing guidelines that are difficult to follow or
differ in thresholds for treatment which often change over
time have previously been identified as barriers for imple-
menting guideline recommendations.[10] In the Nether-
lands, this has lead to the development of a national
multidisciplinary guideline for cardiovascular risk manage-
ment that became available in 2006.
Practice organisation is an issue of continuous concern in
chronic disease management. GPs see problems within
their own practice organisation. Lack of adequate work
routines and high workload have been recognized before
as barriers to provide adequate coronary preven-
tion.[9,10] When structured management in introduced
in general practice, the management of patients with dia-
betes can improve.[23,24] Furthermore, GPs mentioned
problems at the primary-secondary care interface. GP are
reluctant to interfere with the treatment when a patient is
seeing a specialist. This problem has been observed before
as barrier to implement guideline recommendations in
general practice.[25]
Strengths and limitations
This study focussed on the perceptions of GPs, and there-
fore the role of the patients is only commented upon from
their physicians' point of view. We interviewed GPs in one
region of the Netherlands who had indicated that they
were familiar with the guideline recommendations
regarding lipid-lowering treatment in patients with diabe-
tes. Our findings could be limited by this selection but
several of the themes that we have captured were quite
similar to those observed in other primary care settings.
Although the organisation of diabetes care might differ
between countries, issues of structured management,
shared care, and continuity of care are relevant for most
diabetes care settings.[26]
We reached data saturation after 7 interviews, with many
themes mentioned by most GPs, suggesting that our pur-
poseful sampling to include variation on practice organi-
zation and location was not meaningful. There are no
explicit guidelines of determining the saturation point,
and it is therefore possible that under representation of
specific GPs has affected our outcomes.[27] Although this
does not alter the reasons identified in our study, we may
have missed some additional reasons for not prescribing
lipid-lowering medication to patients with diabetes.
A qualitative approach is seen as the best method for stud-
ying reasons underlying treatment decisions. The inter-
views were held in a non-confrontational way to avoid
defensive reactions. We used actual patients to elicit argu-
ments and thoughts of the GPs derived from practice, and
not from general professional ideas. This method is rela-
tively new and may encourage more relevant results than
a more open interview method.[10]
Conclusion
Some of the barriers mentioned by GPs for not prescribing
lipid-lowering medication to patients with diabetes seem
to be valid reasons, showing that guideline non-adher-
ence can be quite rational. On the other hand, the treat-
ment could improve by addressing issues, such as lack of
knowledge or motivation of both the patient and the GP.
More structured management of these patients in general
practice may also lead to better treatment. Finally, this
study suggests that the quality of prescribing performance
should not be assessed at one point in time, since there
may be temporary, valid reasons for not yet prescribing
specific medication.
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